drugset / Trial / NCT02059499

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

NCT02059499

RandomizedCrossoverSingle-blindTreatment

Summary

This randomized phase III trial studies imiquimod or fluorouracil to see how well they work compared to observation in treating patients with high-grade anal squamous skin lesions who are human immunodeficiency virus (HIV)-positive. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether imiquimod or fluorouracil is more effective than observation in treating high-grade anal squamous skin lesions.

Timeline

Start
2015-12-28
Primary completion
2023-12-05
Completion
2024-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Imiquimod Other / unclassified 2.5 % Other
Subject fluorouracil Small molecule 5 % Other